Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 19/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026424 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4026428 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6180681 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6180684 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5144750 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5144748 | 0.82 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028742 | 0.81 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028736 | 0.81 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL7453034 | 0.81 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4035326 | 0.80 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.